Ociperlimab - BeiGene
Alternative Names: Anti-TIGIT monoclonal antibody - BeiGene; BGB-A1217; WCD-118Latest Information Update: 15 May 2024
At a glance
- Originator BeiGene
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Cervical cancer; Liver cancer; Small cell lung cancer; Squamous cell cancer
- Phase I/II Diffuse large B cell lymphoma
- No development reported Solid tumours
Most Recent Events
- 08 May 2024 BeiGene completes enrolment in its phase III Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in the US, Germany, Poland, Netherland, Italy and France (IV) (NCT04746924) (EudraCT2020-004985-21)
- 05 Apr 2024 Efficacy and adverse events data from the phase II AdvanTIG204 trial in Small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (IV, Injection)